Auna S.A. Class A (AUNA) AI Stock Analysis

Compare

258 Followers

Top Page

Auna S.A. Class A

(NYSE:AUNA)

Rating:69Neutral

Price Target:

$7.00

▲(9.72%Upside)

Auna S.A. Class A's overall score is primarily influenced by its strong financial performance, particularly in revenue growth and operational efficiency. However, high leverage, declining cash flow growth, and bearish technical indicators weigh on the stock's prospects. The reasonable valuation offers some support but is offset by potential financial risks and lack of dividend yield.

Auna S.A. Class A (AUNA) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$473.68M

Dividend YieldN/A

Average Volume (3M)51.47K

Price to Earnings (P/E)11.2

Beta (1Y)0.99

Revenue Growth6.97%

EPS GrowthN/A

CountryUS

Employees14,605

SectorGeneral

Sector StrengthN/A

IndustryMedical - Care Facilities

Share Statistics

EPS (TTM)0.20

Shares Outstanding30,095,388

10 Day Avg. Volume26,428

30 Day Avg. Volume51,472

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)1.10

Price to Sales (P/S)0.00

P/FCF Ratio3.56

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$7.90

Price Target Upside23.82% Upside

Rating ConsensusHold

Number of Analyst Covering1

Auna S.A. Class A Business Overview & Revenue Model

Company DescriptionAuna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.

How the Company Makes MoneyAuna S.A. generates revenue primarily through the provision of healthcare services, including hospital stays, outpatient care, and specialized medical treatments. The company operates a network of hospitals and clinics where it charges patients and insurance companies for medical services rendered. Additionally, Auna may receive income from partnerships with healthcare insurers and government healthcare programs, which subsidize or directly pay for services provided to covered patients. The company's focus on expanding its healthcare facilities and services helps drive patient volume and, consequently, revenue growth.

Auna S.A. Class A Earnings Call Summary

Earnings Call Date:May 20, 2025

(Q3-2024)

% Change Since: -8.86%|

Next Earnings Date:Aug 19, 2025

Earnings Call Sentiment Positive

The earnings call highlighted significant growth in adjusted EBITDA, revenue growth in key markets like Mexico and Peru, and improvement in debt leverage. However, challenges in Colombia, specifically related to provisions for impairment losses, pose a concern. Overall, the positive developments in various regions and financial metrics outweigh the challenges faced in Colombia.

Q3-2024 Updates

Positive Updates

Record Adjusted EBITDA Growth

Adjusted EBITDA increased by 23% on an FX-neutral basis with a margin expansion of 1.4 percentage points. Mexico and Peru reached record highs with Mexico's adjusted EBITDA increasing by 34%.

Revenue Growth in Key Markets

Regional platform revenues increased by 13% year-over-year to PEN 1.1 billion, led by Mexico and Peru, which grew 16% and 13%, respectively.

Debt Leverage Improvement

Net debt to adjusted EBITDA ratio fell below 4x to 3.7x, marking the eighth consecutive quarter of improving leverage since the acquisition in 2022.

Positive Performance in Peru

Revenue grew 13% with adjusted EBITDA increasing nearly 50%, and margin expanded by 5.3 percentage points to 21.6%.

Negative Updates

Challenges in Colombia

Adjusted EBITDA decreased by 18% due to increased provisions for impairment losses, impacting the margin which decreased by 4.5 percentage points to 12.4%.

Provision for Impairment Losses

Increased provision for impairment losses in Colombia by PEN 16 million due to less predictable payments from payers.

Company Guidance

During the third quarter 2024 earnings call for Auna, the company provided guidance that highlighted significant financial metrics and strategic outlooks. Adjusted EBITDA increased by 23% year-over-year on an FX-neutral basis, with margins expanding by 1.4 percentage points. In terms of regional performance, Mexico and Peru saw record highs in adjusted EBITDA, with Mexico's adjusted EBITDA increasing by 34% and its margin growing by 4.7 percentage points to nearly 36%. Auna's overall regional platform revenues grew by 13% to PEN 1.1 billion, driven by 16% growth in Mexico and 13% in Peru. The company's debt leverage improved, with the net debt to adjusted EBITDA ratio falling below 4x for the first time since the acquisition in Mexico, marking the eighth consecutive quarter of leverage reduction. Additionally, consolidated revenue grew 13% and adjusted EBITDA increased 23% on an FX-neutral basis, while the margin improved by 1.4 percentage points to over 22%. The company remains optimistic about its long-term growth strategies in Mexico and Colombia, with a focus on implementing the AunaWay and expanding its oncological services.

Auna S.A. Class A Financial Statement Overview

Summary

Auna S.A. Class A shows strong revenue growth and operational efficiency with improving profit margins. However, high leverage and declining free cash flow growth signal potential financial risks. The company should focus on enhancing cash flow management and reducing debt to ensure sustainable financial health.

Income Statement

Positive

Auna S.A. Class A exhibits strong revenue growth with a TTM revenue increase of 12.37% from 2023 to 2024. The gross profit margin has improved to 38.88% TTM, indicating efficient cost management. However, the net profit margin remains modest at 3.65% TTM, largely due to higher operational costs. The EBIT and EBITDA margins are healthy at 17.02% and 23.91% TTM, respectively, reflecting robust operational performance.

Balance Sheet

Positive

The company's debt-to-equity ratio is relatively high at 2.46 TTM, suggesting significant leverage which might pose financial risk. However, a return on equity of 10.47% TTM indicates decent profitability for shareholders. The equity ratio stands at 21.49% TTM, showing limited asset financing through equity, which could impact financial flexibility.

Cash Flow

Positive

Auna has experienced a decline in free cash flow growth with a decrease of 18.23% TTM, which could indicate potential liquidity concerns. The operating cash flow to net income ratio is robust at 3.90 TTM, suggesting strong cash generation capability. However, the free cash flow to net income ratio is lower at 2.97 TTM, implying a need for improved cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.39B	3.88B	2.45B	1.92B	1.44B
Gross Profit	1.73B	1.44B	879.70M	686.93M	529.43M
EBITDA	975.27M	647.30M	299.14M	170.15M	108.36M
Net Income	110.27M	-253.92M	-85.61M	-26.47M	-7.10M
Balance Sheet
Total Assets	7.08B	7.69B	6.59B	2.82B	2.65B
Cash, Cash Equivalents and Short-Term Investments	335.97M	334.26M	208.69M	138.77M	343.45M
Total Debt	3.77B	3.92B	3.51B	1.49B	1.35B
Total Liabilities	5.46B	5.91B	5.04B	2.28B	2.00B
Stockholders Equity	1.48B	1.47B	1.06B	495.82M	600.93M
Cash Flow
Free Cash Flow	577.64M	417.25M	10.67M	-106.03M	27.38M
Operating Cash Flow	668.50M	582.41M	162.64M	183.34M	156.30M
Investing Cash Flow	-236.82M	-173.15M	-3.21B	-291.99M	-125.93M
Financing Cash Flow	-418.12M	-370.00M	3.13B	-102.13M	272.70M

Auna S.A. Class A Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price6.38

Price Trends

50DMA

6.53

Negative

100DMA

6.90

Negative

200DMA

7.10

Negative

Market Momentum

MACD

-0.03

Negative

RSI

50.99

Neutral

STOCH

74.40

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUNA, the sentiment is Neutral. The current price of 6.38 is above the 20-day moving average (MA) of 6.31, below the 50-day MA of 6.53, and below the 200-day MA of 7.10, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.99 is Neutral, neither overbought nor oversold. The STOCH value of 74.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AUNA.

Auna S.A. Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (56)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BTMD	71 Outperform	$150.88M	6.71	-7.92%	―	6.44%	322.20%
AUNA	69 Neutral	$473.68M	11.19	9.93%	―	6.97%	―
Sector *	56 Neutral	$5.79B	21.50	-28.61%	5.76%	10.78%	-34.04%
DCGO	50 Neutral	$137.76M	12.68	-0.21%	―	-26.00%	-103.18%
CMPS	47 Neutral	$364.89M	―	-60.67%	―	―	3.88%
PIII	43 Neutral	$45.64M	―	-131.17%	―	9.79%	-47.01%
CCM	40 Underperform	$23.88M	―	14.03%	―	-29.82%	-2.57%

* General Sector Average

Performance Comparison

AUNA

Auna S.A. Class A

6.40

-2.69

-29.59%

CCM

Concord Medical Services

5.40

-2.70

-33.33%

CMPS

COMPASS Pathways

3.88

-3.39

-46.63%

DCGO

DocGo

1.42

-1.79

-55.76%

PIII

P3 Health Partners

6.50

-21.30

-76.62%

BTMD

biote

4.17

-3.67

-46.81%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 05, 2025